Why Banca IFIS Earnings Are Drawing Investor Attention Banca IFIS (BIT:IF) just reported half year 2026 results that show a sharp contrast between higher net interest income of €271.6 million and a much lower net income of €7.8 million versus last year. See our latest analysis for Banca IFIS. Against this earnings backdrop, Banca IFIS shares trade at €14.9, with a 30 day share price return of 14.97% after a sharp year to date decline of 41.84% and a 1 year total shareholder return that is...

The Milano-Cortina Winter Olympics are estimated to generate €5.3bn in total economic value, including €2.3bn in tourism spending.View on euronews

Banca Ifis (STU:0I6) reports strong net income and maintains a solid capital position despite Eliity integration costs and market challenges.

If you are weighing your next move with Banca IFIS, you are not alone. After all, the stock has served up a mix of intrigue and promise this year, catching plenty of attention across the financial landscape. In the past week, the share price edged down just 0.8%, but zoom out a bit and the bigger story comes into focus. The stock is up 4.1% over the past month, 9.2% year to date, and a striking 20.5% over the past twelve months. Stretch that time frame further, and Banca IFIS has rewarded...

The cider brand has added a high-contrast NaviLens QR code to its cans.

BioReference health, JPMorgan Chase and an Italian fashion retailer are making the job cuts amid market uncertainty

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.

Novartis will acquire Tourmaline Bio for $48 per share, valuing the New York-based biopharmaceutical company at $1.4 billion on a fully diluted basis, the Swiss pharma giant said on Tuesday. Tourmaline is focused on developing pacibekitug, a promising targeted therapy with the potential to reduce systemic inflammation, as a treatment option for atherosclerotic cardiovascular disease, Novartis said in a statement. With the deal, Novartis will acquire a Phase III-ready asset that will complement its existing cardiovascular disease portfolio, it said.